en · de · es · fr · pt
tb-500-notes.peptides6908.com › Guide › Thymosin Beta-4 Fragment Identity — Explained

Thymosin Beta-4 Fragment Identity — Explained

By Editorial Desk · published 2026-06-09 · last reviewed 2026-07-08 · Guide

freeze-thaw cycling comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.

Updated 2026-07-08. Numbers and descriptions here follow the published literature rather than marketing material.

Thymosin Beta-4 Fragment Identity

No major regulatory agency has approved TB-500 for therapeutic use, and it holds no pharmacopoeial monograph. The name appears on the World Anti-Doping Agency prohibited list within the class covering peptide hormones, growth factors, and related substances. Detection in doping control relies on mass spectrometric methods applied to urine, often after preparation steps that concentrate the analyte. Discussion of TB-500 therefore clusters in biochemistry, sports medicine, and anti-doping literature rather than in registered clinical trials.

TB-500 is a synthetic peptide preparation marketed under a name derived from thymosin beta-4, a 43-residue actin-binding protein first isolated from thymus tissue. The full-length protein has a reported molecular mass near 4963 Da, while material sold as TB-500 is often described as a fragment containing the actin-binding motif LKKTETQ. Because suppliers use the name inconsistently, published sources sometimes refer to the same label as a fragment, a synthetic copy, or a related analog. This naming ambiguity complicates direct comparison of reports across studies.

Laboratory work on thymosin beta-4 describes binding to monomeric actin and effects on cell migration, angiogenesis, and inflammatory signaling in cultured cells. Animal models have examined skin, corneal, and cardiac repair after injury, with outcomes reported mainly in preclinical literature. Most of that evidence concerns the parent protein rather than preparations labelled TB-500, so extrapolation from animal findings to a specific commercial product remains uncertain. Whether the two behave identically in living systems has not been established in controlled human studies.

Identity and Physical Form

Material sold under this label typically arrives as a freeze-dried powder in a sealed vial with a certificate of analysis. Such certificates usually report reversed-phase chromatography purity plus a mass confirmation, and stated purities commonly sit between 95 and 99 percent. Counter-ion identity, residual trifluoroacetate, water content, and peptide net weight are separate specifications that a certificate may or may not include. A purity figure alone does not establish sequence identity, so independent mass verification remains the practical check.

The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.

The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.

Tb-500 at a glance

PropertyValueNotes
Molecular massApproximately 4963 Da for full-length thymosin beta-4Value applies to the parent protein; fragment products may differ
AppearanceWhite to off-white lyophilized powderTypical form of supplied synthetic peptide
SolubilityFreely soluble in waterPolar peptide; dissolves readily in aqueous buffer
Storage of dry powder−20 °C, desiccated, protected from lightStandard laboratory practice for peptides
Typical detection methodLiquid chromatography–tandem mass spectrometryUsed in purity testing and anti-doping analysis

Handling, Storage and Quality Checks

Dry peptide powder is commonly kept at −20 °C in a desiccated container away from light, a practice that limits moisture uptake and oxidation. Once dissolved, solutions are generally held at 2–8 °C for short periods or frozen at −20 °C or lower for longer storage, with repeated freeze-thaw cycles avoided. Hydrolysis and oxidation are the main degradation routes for peptides in solution, and both accelerate at higher temperature or extreme pH. Published stability data specific to TB-500 are limited, so shelf life should be treated as uncertain.

Identity and purity checks for peptide material typically combine reversed-phase high-performance liquid chromatography with mass measurement, since retention time alone cannot confirm a sequence. Mass measurement verifies the expected molecular mass within instrument tolerance, while chromatographic peak area provides a purity estimate. Anti-doping analysis of urine uses related but more sensitive workflows, sometimes after solid-phase extraction. For research material, batch documentation, certificate content, and independent testing are common points of scrutiny, because supply chains outside pharmaceutical regulation vary widely in the paperwork they provide.

Reconstitution of a lyophilized peptide is normally done with sterile water or a suitable buffer under aseptic conditions. Adding solvent down the vial wall and allowing gentle dissolution instead of vigorous vortexing reduces the chance of aggregation, which can lower the effective concentration of the resulting solution. Concentrated stocks are usually diluted into working buffer shortly before use. Because no standard preparation protocol exists for TB-500 specifically, laboratories adapt general peptide handling practice, and reported results may reflect differing preparation choices.

Related pages on this site

Research Framing and Evidence Base

Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.

Biological interest in this peptide centers on its relationship to actin dynamics. Thymosin beta-4 binds monomeric actin through an LKKTET motif, and a short sequence carrying that motif can compete with other actin-binding proteins in cell-free preparations. Investigators propose that such competition shifts the balance between filament assembly and disassembly, which in turn affects how readily a cell extends protrusions and migrates. Most of the supporting observations come from cultured cells and purified protein systems rather than from intact organisms.

TB-500 Background and Identity

Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.

TB-500 is a catalogue name applied to a synthetic peptide related to thymosin beta-4, an actin-binding protein found in most mammalian cells. Suppliers do not use the label consistently: some describe it as the full 43-residue protein, others as a short fragment from the actin-binding region, and others as a related tetrapeptide. Because the name is commercial rather than chemical, two products sold under it may not contain the same molecule. This naming ambiguity is the first point to check in any description of the material.

Thymosin Beta-4 Fragment Background

Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.

TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.

Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.

Reference notes

A collection of reprints of notable reviews from the magazine's history, along with retrospective commentary on each game. In addition to reviews of popular titles (including the three "ten out of ten" scores that had been awarded during that period), it also included Edge's comments on notable hyped disappointments such as Rise of the Robots and Daikatana. The issue also included an index of the content of those 100 issues of the magazine. "Retro: The guide to classic videogame playing and collecting" (2002)

For the [Special Rapporteur on the right to health], the dominance of the biomedical model to explain emotional distress has resulted in the overuse of medicalisation and institutionalisation, while ignoring the social, political or existential contexts that contribute to manifestations of mental distress.

(2026) study the anatomy of ulna and femur or Sahelanthropus tchadensis, interpreted as indicative of presence of adaptations to bipedalism in spite of similarities in size and geometric morphometric shape to bones of chimpanzees. De Jager et al. (2026) study the frequency, position, and variability of cortical sulcal imprints in endocasts of extant chimpanzees and bonobos, providing a comparative resource for the studies of the brain evolution based on hominin fossils. Dunbar (2026) reevaluates data from the study of Deaner & Nunn (1999), finds evidence of changes in brain size following increases in body size in the evolution of primates but in a more complicated way that suggested by the original brain lag hypothesis, with an increase in body size followed by a progressively greater increase in brain size, and finds evidence of such evolution of brain and body size in hominins.

Lactic acid bacteria are fastidious organisms that cannot synthesize on their own all of their complex nutritional requirements. For LAB to grow and complete malolactic fermentation, the constitution of the wine medium must provide for their nutritional needs. Like wine yeast, LAB require a carbon source for energy metabolism (usually sugar and malic acid), nitrogen source (such as amino acids and purines) for protein synthesis, and various vitamins (such as niacin, riboflavin, and thiamine) and minerals to assist in the synthesis of enzymes and other cellular components. The source for these nutrients is often found in the grape must itself, though MLF inoculations that run concurrent with alcoholic fermentation risk the yeast outcompeting the bacteria for these nutrients. Towards the end of fermentation, while most of the original grape must resources have been consumed, the lysis of dead yeast cells (the "lees") can be a source for some nutrients, particularly amino acids. Plus, even "dry" wines that have been fermented to dryness still have unfermentable pentose sugars (such as arabinose, ribose and xylose) left behind that can be used by both positive and spoilage bacteria. As with wine yeast, manufacturers of cultured LAB inoculum usually offer specially prepared nutritional additives that be used as a supplement. However, unlike wine yeast, lactic acid bacteria can not use the supplement diammonium phosphate as a nitrogen source.

== Economy == Fishing is the primary occupation. The islands have strategic and economic value, in terms of fisheries and also mineral deposits of pyrite, sulfur, and various polymetallic ores. There are hopes that oil exploration will provide an economic boost to the islands. In 2014, construction workers built a pier and a breakwater in Kitovy Bay, central Iturup, where barges are a major means of transport, sailing between the cove and ships anchored offshore. A new road has been carved through the woods near Kurilsk, the island's biggest village, going to the site of Iturup Airport (on Kunashir, the neighboring island south of Iturup, there exists Yuzhno-Kurilsk Mendeleyevo Airport). Gidrostroy, the Kurils' biggest business group with interests in fishing, construction and real estate, built its second fish processing factory on Iturup island in 2006, introducing a state-of-the-art conveyor system. To deal with a rise in the demand of electricity, the local government is also upgrading a state-run geothermal power plant at Mount Baransky, an active volcano, where steam and hot water can be found. In 2022, a special economic zone was established on the Kuril islands with special tax regimes, exemption from corporate income tax, VAT with reduced customs duties for 20 years. It is an important part of Russian government's plan to develop the Russian far east.

Sources: en.wikipedia.org

Notes from published material

Once the heterologous protein has been fused with the bacterial cell surface protein, it is exposed to either an enzyme, a cell (expressing a target protein) or an antibody (usually fluorescently tagged), depending on the application of the experiment. The sample is then passed through a beam of light during FACS, in a very narrow stream of fluid so that only one cell can pass at a time, and the fluorescence emitted is detected. Information on the size of the cell can be obtained by the scattering of light and if binding of the heterologous protein with the target protein/cell has occurred, there will be more fluorescence emitted. Bacterial surface display can be used for a variety of applications. These include affinity-based screening, antibody epitope mapping, the identification of peptide substrates, the identification of cell-binding peptides and vaccine generation.

=== Discovery === In 1938, Emilio Segrè and Glenn T. Seaborg isolated for the first time the metastable isotope technetium-99m, after bombarding natural molybdenum with 8 MeV deuterons in the 37-inch (940 mm) cyclotron of Ernest Orlando Lawrence's Radiation laboratory. In 1970 Seaborg explained that:

Lithium-ion batteries are used in a multitude of applications, including consumer electronics, toys, power tools, electric vehicles and backup power in telecommunications applications. Lithium-ion batteries are also used for grid energy storage. Some submarines have also been equipped with lithium-ion batteries.

Like its menu, the equipment the company cooks its hamburgers with has also evolved as the company expanded. The burgers have always been broiled mechanically; the original unit, called an Insta-Broiler, was one of two pieces of equipment the founders of Insta-Burger King purchased before opening their new restaurant. The Insta-Broiler worked by cooking 12 burger patties in a wire basket, allowing the patties to be cooked from both sides simultaneously. When McLamore and Edgerton took over the company, besides dropping the "Insta-" prefix, they switched to an improved unit called a "Flame Broiler". Designed by the two and featuring stationary burners that cooked the meat on a moving chain, the unit broke down less often while maintaining a similar cooking rate. The company would stay with that format for the next 40 years until Burger King began developing a variable speed broiler that could handle multiple items with different cooking rates and times. These new units began testing in 1999 and eventually evolved into the two models the company deployed system-wide in 2008–2009. Accompanying these new broilers was new food-holding equipment, accompanied with a computer-based product monitoring system for its cooked products. The monitoring system allows for more concise tracking of product quality while giving the company and its franchisees a method to streamline costs by more precisely projecting sales and product usage.

Sources: en.wikipedia.org

Background from the literature

at the top. Each layer of fluid moves faster than the one just below it, and friction between them gives rise to a force resisting their relative motion. In particular, the fluid applies on the top plate a force in the direction opposite to its motion, and an equal but opposite force on the bottom plate. An external force is therefore required in order to keep the top plate moving at constant speed. In many fluids, the flow velocity is observed to vary linearly from zero at the bottom to

Digestible Indispensable Amino Acid Score (DIAAS) is a protein quality method proposed in March 2013 by the Food and Agriculture Organization to replace the current protein ranking standard, the Protein Digestibility Corrected Amino Acid Score (PDCAAS). The DIAAS accounts for amino acid digestibility at the end of the small intestine (= the end of ileum, the last section of the small intestine), providing a more accurate measure of the amounts of amino acids absorbed by the body and the protein's contribution to human amino acid and nitrogen requirements. This is in contrast to the PDCAAS, which is based on an estimate of total protein digestibility over the total digestive tract. Values stated using PDCAAS generally overestimate the amount of amino acids absorbed.

I would guess if we had gone in there, we would still have forces in Baghdad today. We'd be running the country. We would not have been able to get everybody out and bring everybody home. And the final point that I think needs to be made is this question of casualties. I don't think you could have done all of that without significant additional US casualties, and while everybody was tremendously impressed with the low cost of the conflict, for the 146 Americans who were killed in action and for their families, it wasn't a cheap war.

=== Tau in Frontotemporal Lobar Degeneration (FTLD) === The tau protein is one of the most common aggregated proteins in frontotemporal lobar degeneration (FTLD), the pathology underlying FTD disorders, the other being TDP-43. While protein aggregation underlies FTLD tauopathies, the specific tau isoforms present and the morphology of the aggregates vary across subtypes. FTLD tauopathies are predominantly associated with the 3R and 4R tau isoforms. The “Pick bodies” characteristic of the FTLD tauopathy known as “Pick’s disease” is associated with 3R tau. Progressive supranuclear palsy (PSP) and corticobasal syndrome/degeneration (CBS/CBD), meanwhile, are associated with the 4R isoform. There is evidence that a ratio of 3R and 4R tau is essential for preventing neurodegeneration, and that alterations in this ratio are believed to drive FTLD and related disorders without requiring co-occurrence with other pathologies. FTD-tau appears to be sporadic in the majority of people diagnosed, but researchers do not yet fully understand the pathological mechanisms. Inherited pathogenic variants in the MAPT gene, however, are responsible for a fraction of people diagnosed with FTD-tau. Within and between families, FTD due to MAPT presents with significant heterogeneity in the symptoms that may be present, underscoring the possibility for genetic modifiers and environmental factors to influence clinical presentation. Intronic variants in MAPT, and most variants in exon 10, affect the 3R/4R tau ratio, contributing significantly to the development of FTLD pathology.

Physical side effects included pupil dilation, tingling, trembling, numbness, sweating, lightheadedness, athetosis, slight nausea, and increased heart rate and blood pressure. In addition to parenteral DMT, Shulgin described the effects of oral DMT plus harmaline or in some cases Peganum harmala seeds in TiHKAL. The effects were reported to include closed-eye imagery such as colors, infinitely repeated and wavy sheets of patterns, and kaleidoscopic images, visual changes like brighter colors and patterns and distortions, music enhancement, time distortion, clarity, insights, intoxication, emotional changes, feeling alive and excited, depression, despair, and feeling psychotic. Other effects included difficulty focusing on thoughts, short-term memory disruption, feeling cold, nausea, gait impairment or difficulty walking, and an afterglow. The preceding effects are variably due to both DMT and harmaline, with harmaline also producing its own hallucinogenic effects at sufficiently doses, for instance 150 mg or more.

Sources: en.wikipedia.org

Frequently asked questions

Is TB-500 the same as thymosin beta-4?

Not necessarily. TB-500 is a commercial label that suppliers apply to synthetic peptides described as thymosin beta-4 or a fragment of it. Published research most often studies the full-length protein, so statements about one do not automatically transfer to the other.

Has any regulator approved TB-500 for medical use?

No. No major regulatory authority lists an approved product under this name, and no pharmacopoeial monograph exists for it. Material sold under the label is therefore supplied outside approved pharmaceutical channels, which affects the quality documentation available.

Why does TB-500 appear in anti-doping literature?

It falls within a prohibited class covering peptide hormones and growth factors, based on presumed effects on tissue repair and blood vessel formation. Anti-doping laboratories have published mass spectrometry methods for detecting thymosin beta-4 related peptides in urine samples.

Is TB-500 the same substance as thymosin beta-4?

Usually not, though usage overlaps. The label most often refers to a short acetylated fragment of the parent protein, while thymosin beta-4 itself is the full 43-residue molecule. Because suppliers vary, a sequence statement is needed to settle the question for any particular lot.

Network